Evidence map›Paper›PMID 30633742›Full record

ArticlePLoS neglected tropical diseases2019

DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica.

Elham Gholami, Fabiano Oliveira, Tahereh Taheri, Negar Seyed, Safoora Gharibzadeh, Nasim Gholami, Amir Mizbani, Fatemeh Zali, Sima Habibzadeh, Daniel Omid Bakhadj and 9 more

Expression of concernErratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Expression ofJournal of arthropod-borne diseases · 2024
    Article
  3. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024
    Review
  4. Article
  5. Anti-leishmaniasis Effect ofAdvanced biomedical research · 2023
    Article
  6. Review
  7. Article
  8. Frontiers in immunology · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Frontiers in cellular and infection microbiology · 2020
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Elham GholamiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Fabiano OliveiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.ORCID 0000-0002-7924-8038
Tahereh TaheriDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Negar SeyedDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Safoora GharibzadehDepartment of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0003-4535-4040
Nasim GholamiDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Amir MizbaniDepartment of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-5875-7514
Fatemeh ZaliDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Sima HabibzadehDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Daniel Omid BakhadjVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
Claudio MenesesVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
Kambiz Kamyab-HesariDepartment of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Alireza SadeghipourDepartment of Pathology, Hazrat-e-Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Yasaman TaslimiDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Fatemeh KhadirDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0001-9969-9322
Shaden KamhawiVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
Mohammad Ali MazlomiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Jesus G ValenzuelaVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.ORCID 0000-0002-5589-9450
Sima RafatiDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0002-7221-1320
Pasteur Institute of Iran · IRNational Institutes of Health · USETH Zurich · CHIran University of Medical Sciences · IRRazi Hospital · IRTehran University of Medical Sciences · IR

Funding

Molecular approaches to understand vector-host and vector-pathogen interactionsZIAAI000932 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VALENZUELA, JESUS · 2009 to 2025
$23.1M
6 · The paper itself

Abstract

backgroundThe vector-borne disease leishmaniasis is transmitted to humans by infected female sand flies, which transmits Leishmania parasites together with saliva during blood feeding. In Iran, cutaneous leishmaniasis (CL) is caused by Leishmania (L.) major and L. tropica, and their main vectors are Phlebotomus (Ph.) papatasi and Ph. sergenti, respectively. Previous studies have demonstrated that mice immunized with the salivary gland homogenate (SGH) of Ph. papatasi or subjected to bites from uninfected sand flies are protected against L. major infection. METHODS AND

resultsIn this work we tested the immune response in BALB/c mice to 14 different plasmids coding for the most abundant salivary proteins of Ph. sergenti. The plasmid coding for the salivary protein PsSP9 induced a DTH response in the presence of a significant increase of IFN-γ expression in draining lymph nodes (dLN) as compared to control plasmid and no detectable PsSP9 antibody response. Animals immunized with whole Ph. sergenti SGH developed only a saliva-specific antibody response and no DTH response. Mice immunized with whole Ph. sergenti saliva and challenged intradermally with L. tropica plus Ph. sergenti SGH in their ears, exhibited no protective effect. In contrast, PsSP9-immunized mice showed protection against L. tropica infection resulting in a reduction in nodule size, disease burden and parasite burden compared to controls. Two months post infection, protection was associated with a significant increase in the ratio of IFN-γ to IL-5 expression in the dLN compared to controls.

conclusionThis study demonstrates that while immunity to the whole Ph. sergenti saliva does not induce a protective response against cutaneous leishmaniasis in BALB/c mice, PsSP9, a member of the PpSP15 family of Ph. sergenti salivary proteins, provides protection against L. tropica infection. These results suggest that this family of proteins in Ph. sergenti, Ph. duboscqi and Ph. papatasi may have similar immunogenic and protective properties against different Leishmania species. Indeed, this anti-saliva immunity may act as an adjuvant to accelerate the cell-mediated immune response to co-administered Leishmania antigens, or even cause the activation of infected macrophages to remove parasites more efficiently. These findings highlight the idea of applying arthropod saliva components in vaccination approaches for diseases caused by vector-borne pathogens.

Indexed as

AnimalsDisease Models, AnimalFemaleHypersensitivity, DelayedInterferon-gammaLeishmaniasis, CutaneousLeishmania tropicaMice, Inbred BALB CPhlebotomusSalivary Proteins and PeptidesVaccines, DNAInterferon-gammaSalivary Proteins and PeptidesVaccines, DNA

Identifiers

PMID30633742
PMCPMC6345478
OpenAlexW2909324369

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.